ESSPL Activators
ESSPL Activators encompass a range of chemical compounds that either directly or indirectly facilitate the functional activity of ESSPL through diverse signaling cascades and modulatory actions. Forskolin, for instance, raises intracellular cAMP, subsequently activating PKA which may phosphorylate ESSPL, thus enhancing its activity. Similarly, PMA, by activating PKC, could also phosphorylate ESSPLor induce changes in protein-protein interactions, potentially leading to an increase in ESSPL activity. Ionomycin, by elevating intracellular calcium, might activate CaMK, which could directly modify ESSPL's activity through phosphorylation or conformational shifts. Similarly, thapsigargin and A23187, both manipulators of intracellular calcium levels, may indirectly augment ESSPL activity through calcium-dependent pathways, suggesting a role for ESSPL in calcium signal transduction. EGCG contributes to ESSPL activation by inhibiting other kinases, thereby potentially preventing phosphorylation on inhibitory sites or altering signaling networks in favor of those that activate ESSPL. Okadaic acid, by maintaining ESSPL in a phosphorylated state through the inhibition of phosphatases, could enhance its activity, assuming ESSPL's function is modulated by phosphorylation.
Continuing with the theme of phosphorylation, LY294002's inhibition of the PI3K pathway may reroute signaling towards ESSPL activation by altering feedback loops or engaging alternate pathways that support ESSPL function. In a different vein, retinoic acid could modulate ESSPL activity by affecting gene expression patterns that influence its stability or interaction with other proteins. The cAMP analog 8-Bromo-cAMP, through PKA activation, can also lead to the phosphorylation and subsequent activation of ESSPL, assuming that ESSPL is a PKA substrate. Lastly, staurosporine, despite its general kinase inhibition, may paradoxically allow for the specific activation of ESSPL pathways by alleviating the inhibitory phosphorylation exerted by certain kinases or by promoting other signaling mechanisms that enhance ESSPL functions. Collectively, these activators work through a variety of mechanisms to promote the functional activity of ESSPL, highlighting the complexity of cellular signaling networks and the intricate role of ESSPL within these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, which increases intracellular levels of cAMP. Elevated cAMP activates protein kinase A (PKA), which could then phosphorylate ESSPL, leading to its functional activation through possible phosphorylation-dependent changes in its activity or localization. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC has a wide range of substrates and can phosphorylate ESSPL, potentially enhancing its activity through direct phosphorylation or modulation of its interaction with other proteins. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium levels. The increase in calcium can activate calcium-dependent protein kinases, such as calmodulin-dependent kinase (CaMK), which might then phosphorylate ESSPL or alter its activity through calcium-dependent conformational changes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a known inhibitor of various protein kinases. By inhibiting competitive signaling pathways, it may upregulate the activity of ESSPL by reducing phosphorylation on inhibitory sites or redirecting signaling flow towards pathways that activate ESSPL. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
This compound is a potent inhibitor of protein phosphatases PP1 and PP2A. By inhibiting dephosphorylation, okadaic acid could lead to a sustained phosphorylation state of ESSPL, which might enhance its activity if ESSPL function is regulated by phosphorylation status. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, which can trigger signaling pathways involving MAPK, PI3K/Akt, and PLC, potentially leading to the activation of ESSPL through downstream kinases or altered protein-protein interactions. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium levels, which can activate calcium-dependent signaling pathways. This may indirectly activate ESSPL by promoting its interaction with other proteins or by altering its conformation to an active state. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid is a metabolite of vitamin A that modulates gene expression through retinoic acid receptors. It can influence signaling pathways that alter protein stability, localization, or interaction networks, potentially leading to increased activity of ESSPL. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
This cAMP analog is resistant to degradation by phosphodiesterases. It activates PKA, which could then phosphorylate ESSPL, resulting in enhanced activity if phosphorylation activates ESSPL or changes its interaction with other proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling through the Akt pathway. By inhibiting this pathway, LY294002 could shift signaling towards pathways that activate ESSPL, possibly through relief of negative feedback loops or enhancement of alternative signaling cascades that promote ESSPL activity. | ||||||